| 基于对异丙基甲苯和二甲基双胍的对称双核钌(Ⅱ)配合物的合成及其体外抗癌活性 |
| Symmetrical Diruthenium(Ⅱ) Complex Based on 1-Isopropyl-4-methylbenzene and Dimethylbiguanide: Synthesis and Anticancer Activity in Vitro |
|
| 摘要: 在碱性水溶液中合成了一种对称双核桥联配合物（NH4）2[Ru（Cym）（L）]2Cl2·4H2O（1）（Cym=对异丙基甲苯，H2L=1，1-二甲基双胍）。采用红外光谱、核磁共振谱和X射线单晶衍射进行了结构表征，结晶水数目由热重分析法得出。采用MTT法测定了其对4种人癌细胞系HepG-2、A549、Hela、MCF-7的细胞毒性，以临床用药顺铂为对照，结果表明该配合物对HepG-2（肝细胞癌，HCC）的作用与顺铂相当。 |
| 关键词: 钌配合物 晶体结构 抗癌活性 顺铂 |
| 基金项目: 江西省教育厅科学技术基金（No.GJJ180907）和江西省卫生健康委科技计划项目（No.202131075）资助。 |
| Abstract: A novel symmetrical dinuclear bridging complex (NH4)2[Ru(Cym)(L)]2Cl2·4H2O (1) (Cym=p-cymene=1-isopropyl-4-methylbenzene, H2L=1,1-dimethylbiguanide) was obtained by treatment of the precursor[Ru(Cym)Cl2]2 with metformin hydrochloride. In aqueous base solution, deprotonation of the proligand (1,1-dimethylbiguanide) occured and the corresponding neutral ruthenium complex 1 was obtained. The structure of complex 1 has been established by FT-IR and NMR spectroscopy and single-crystal X-ray diffraction analysis. The number of crystal water was obtained by thermogravimetric analysis. The inhibition of cell proliferation activity against four human cancer cell lines (HepG-2, A549, Hela, MCF-7) of complex 1 relative to cisplatin was measured by MTT method in vitro. Notably, the novel complex displayed comparable potency toward HepG-2 (hepatocellular carcinoma, HCC) compared to cisplatin. |
| Keywords: ruthenium complex crystal structure anticancer activity cisplatin |
| 投稿时间：2020-09-27 修订日期：2021-03-14 |
| 摘要点击次数: 964 |
| 全文下载次数: 499 |
| 余群英.基于对异丙基甲苯和二甲基双胍的对称双核钌(Ⅱ)配合物的合成及其体外抗癌活性[J].无机化学学报,2021,37(5):899-904. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| Support information: 相关附件： file200456_Supporting_information (2).docx |
|
|
|
|
|
|
